This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Somavert reimbursement in England

Somavert is funded directly by a NHS England specialised commissioning budget via the Blueteq system1​​​​​​​

  • Somavert is excluded from the Payment by Results (PbR) tariff
  • It is not funded through the hospital budget
  • All prescribers for new patients must be registered on the Blueteq system
  • Approval must be granted via Blueteq before prescribing to new patients
  • The hospital pharmacist has an integral role in managing and supporting this process

​​​​​​​To complete a funding application for Somavert and receive automatic approval you will need to confirm that the patient meets each of the 6 criteria for NHS England funding:1,2​​​​​​​​​​​​​​

  • Active acromegaly (continued clinical features of acromegaly (disfiguration, metabolic))
  • Decision to start treatment made by pituitary MDT
  • Baseline IGF-I ≥1.3xULN
  • Incomplete response or unsuitable for pituitary surgery
  • Incomplete response to somatostatin analogue ± radiotherapy (SRS/SRT) or significant adverse drug reactions
  • Will not be given with somatostatin analogue

​​​​​​​To see the full inclusion and exclusion criteria for pegvisomant, visit the clinical commissioning policy here (page 17)

Patients who do not meet the criteria but are funded by an individual funding request (IFR) will continue to receive funding via that route and do not need inclusion into Blueteq

​​​​​​​Watch this step-by-step guide to completing a funding application via Blueteq

Using Blueteq to apply for Somavert funding

This animation explains how to set up a new user account on Blueteq and what information is needed

Somavert NHS England commissioning policy

Dr Simon Aylwin, King's College Hospital, Endocrinology CRG, explains the NHSE policy for pegvisomant and its place in the treatment journey for acromegaly patients

Learn about the pharmacist’s role with Blueteq

Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and Blueteq funding arrangements to homecare service provision

Discover more webinars

Explore more 

Contact us 

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

The patient journey with acrocare

Discover how Blueteq fits within the Somavert prescribing pathway and the different types of homecare we offer

Learn more

References 

1. NHS England A03X01/01 Clinical Commissioning Policy. December 2016. Available here (date accessed: June 2021)
2. Somavert Summary of Product Characteristics. Available here

PP-SOM-GBR-0956. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No